Business Services Industry

CELSION to Hold Fourth Quarter and Fiscal 2007 Financial Results Call Thursday, February 21, 2008

Business Wire, Feb 19, 2008

COLUMBIA, Md. -- CELSION CORPORATION (NASDAQ: CLN), a biotechnology, drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver a high concentrations of proven chemotherapeutics, today reported that It would hold a shareholders' conference call at 11:00 a.m. Eastern Time on Thursday, February 21, 2008. To participate in the call, interested parties can dial 877-604-2080 (U.S./Canada) or 706-902-1383 (International), Conference ID: #35634307 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the Internet at http://www.celsion.com.

The call will be archived for replay February 21, 2008 at 2:00 P.M. until Thursday, February 28, 2008. The replay can be accessed at 800-642-1687 or 706-645-9291, Conference ID: #35634307. The call will also be available on the Company's website, http://www.celsion.com for 90 days after 2:00 p.m. on Thursday, February 21, 2008.

About Celsion:

Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System. Additional information about Celsion Corporation can be found on the Celsion website at www.celsion.com.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale